Compounding Pharmacy Texas: What Patients and Providers Must Know in 2026
Texas has one of the most active compounding pharmacy markets in the country. As of July 2025, 891 Class A, B, C, and E pharmacies in the state perform sterile compounding, according to Texas State Board of Pharmacy (TSBP) licensing data. The nation’s largest 503B outsourcing facility is headquartered in Houston, and a sweeping regulatory overhaul to the state’s sterile compounding rules took effect on March 1, 2026.
That combination creates a paradox. Texas patients and providers have more compounding options than almost anywhere in the United States, yet the regulatory environment has never been more demanding or more rapidly changing. The TSBP §291.133 sterile compounding amendments, the legal end of GLP-1 compounding, the SB 1236 PBM reform law, and rising quality standards like PCAB accreditation have all reshaped the landscape in a matter of months.
This guide explains what patients and providers must understand in 2026: the 503A versus 503B distinction, the new Texas sterile compounding rules, the GLP-1 shutdown, PBM reform, the USP standards behind every compound, and how to identify a trustworthy compounding partner. Throughout, Nationwide Compounding Rx® serves as a reference point: a PCAB-accredited, USP 800-compliant pharmacy that ships to Texas and operates under the model best suited for personalized care.
The Texas Compounding Pharmacy Landscape in 2026
Texas, alongside Florida, anchors compounding activity in the United States. Business-friendly regulations and lower facility costs have drawn the industry to the Southern states, and Texas is at the center of it.
The sector is growing nationally. The U.S. compounding pharmacy market was valued at roughly $6.0 to $6.7 billion in 2024 and 2025 and is projected to reach $10.8 to $11.5 billion by 2034, a compound annual growth rate near 6.2%.
That growth, however, masks real economic pressure. Nearly 7% of Texas pharmacies closed in the year before the state’s landmark PBM reform law passed. For patients and providers, this means choosing a compounding partner is no longer just a clinical decision. Volume of options, regulatory shifts, and the GLP-1 market disruption together demand informed decision-making.
503A vs. 503B: The Distinction Most Patients and Providers Miss
One of the most consequential distinctions in compounding pharmacy is also one of the most misunderstood, and most competitor content ignores it entirely.
503A pharmacies are traditional compounding pharmacies that prepare medications pursuant to a valid, patient-specific prescription. They are regulated primarily by state boards of pharmacy, such as the TSBP. This is the dominant model, representing roughly 72% to 81% of U.S. compounding market revenue.
503B outsourcing facilities are federally registered facilities that can produce large batches of compounded drugs without patient-specific prescriptions, for office use or hospital administration. They are subject to FDA oversight and Current Good Manufacturing Practice (CGMP) standards.
For providers, the practical implication is clear: a 503A pharmacy is the appropriate partner for individualized patient prescriptions such as bio-identical hormone replacement therapy (BHRT), pain management, and pediatric formulations. A 503B facility is suited for bulk office-use purchases.
For patients, the difference matters as well. A prescription filled at a 503A pharmacy is customized for the individual. Medications from a 503B facility are pre-compounded in batches and may not be tailored to specific needs.
Nationwide Compounding Rx® operates as a 503A pharmacy, meaning every compound is prepared pursuant to a valid, patient-specific prescription: the model best suited for personalized care. 503A pharmacies are held to state board standards (including TSBP §291.133) and USP <795> and <797> guidelines, and PCAB accreditation provides an additional layer of third-party quality verification. To learn more about what is compounding and how the process works, patients and providers can explore the pharmacy’s dedicated resource.
The 2026 TSBP §291.133 Sterile Compounding Amendments: What Changed and Why It Matters
The Texas State Board of Pharmacy adopted major amendments to §291.133, the rule governing pharmacies compounding sterile preparations, effective March 1, 2026. It is the most significant update to Texas sterile compounding rules in years.
The process was rigorous. The TSBP established a Compounding Rules Advisory Group with Sterile and Non-Sterile Subcommittees. The rule was proposed, then reproposed after extensive public comment from pharmacists, trade groups, and attorneys, and filed with the Office of the Secretary of State on February 9, 2026.
The core objective is to align Texas rules more closely with updated USP <797> standards in order to reduce patient risk from contamination, infection, or incorrect preparations. Key substantive changes include an increased allowable batch size of up to 750 units (an improvement over the 250-unit maximum in USP <797>), clearer environmental monitoring requirements, and updated beyond-use dating standards.
For providers, the takeaway is direct: pharmacies that cannot demonstrate compliance with the new §291.133 standards represent a compliance and patient safety risk. Providers should verify that compounding partners are operating under the updated rules.
For patients, the amendments strengthen the safety net around sterile preparations, including IV medications, injectables, and eye drops, which carry the highest risk if improperly compounded.
Understanding USP <795>, <797>, and <800>: The Quality Standards Behind Every Compound
USP standards are the technical backbone of compounding pharmacy quality, referenced directly in both TSBP rules and PCAB accreditation requirements.
- USP <795> governs non-sterile compounding such as creams, capsules, troches, and oral liquids. It addresses formulation, stability, packaging, and beyond-use dating for preparations that do not require sterility.
- USP <797> governs sterile compounding such as injectables, ophthalmic preparations, and IV admixtures. It is the standard most directly affected by the March 1, 2026 §291.133 amendments, covering cleanroom design, personnel training, environmental monitoring, and beyond-use dating.
- USP <800> governs the handling of hazardous drugs. It requires specialized containment, personal protective equipment, and facility design to protect staff and prevent cross-contamination. Compliance is now required for PCAB accreditation of pharmacies handling hazardous drugs.
USP <800> compliance is a meaningful differentiator. It protects not only patients but also pharmacy staff, and it signals that a pharmacy has invested in proper facility infrastructure. Not all compounding pharmacies meet this standard. Nationwide Compounding Rx® operates a USP 800-compliant facility, eliminating the possibility of cross-contamination.
When evaluating a compounding pharmacy, asking whether it complies with USP <795>, <797>, and <800>, and whether it is PCAB-accredited, provides a reliable quality filter.
PCAB Accreditation: The Gold Standard for Compounding Pharmacy Quality
PCAB (Pharmacy Compounding Accreditation Board) accreditation, administered through ACHC, is the recognized gold standard for compounding pharmacy quality in the United States. Revised PCAB standards incorporating updated USP <795> and <797> took effect June 1, 2024, meaning accredited pharmacies have already undergone rigorous review under the most current standards.
The American Medical Association recommends that providers partner only with PCAB-accredited pharmacies, a significant clinical endorsement. Accreditation involves on-site inspection, review of policies and procedures, verification of personnel training, assessment of quality control systems, and ongoing compliance monitoring.
Without third-party accreditation, patients and providers have no independent verification of a pharmacy’s safety and quality practices. Nationwide Compounding Rx® has maintained PCAB accreditation since its early days of operation, a long-standing commitment to quality that predates many competitors’ awareness of the standard. Texas patients and providers should verify PCAB accreditation status before establishing a compounding pharmacy relationship.
The GLP-1 Compounding Shutdown: What Texas Patients and Providers Need to Know
From 2022 through 2024, FDA-declared drug shortages of semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) allowed 503A and 503B compounding pharmacies to legally prepare copies of these GLP-1 medications.
In 2026, the FDA proposed to formally exclude semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facility bulk drug substances list, with a public comment period open through June 29, 2026, permanently closing the door on large-scale GLP-1 compounding.
Enforcement is aggressive. In March 2026, the FDA issued 30 warning letters in a single day to telehealth companies making false or misleading claims about compounded GLP-1 products. These enforcement actions illustrate the legal risk for pharmacies that continued compounding after the shortage resolution.
Texas patients currently using compounded GLP-1 medications should consult their prescribers about transitioning to FDA-approved branded products or alternative weight management therapies. Texas providers and weight loss clinics should audit their compounding pharmacy relationships and confirm that any pharmacy they work with has fully wound down GLP-1 compounding operations. Nationwide Compounding Rx® operates in full compliance with FDA regulations and does not compound medications that are no longer legally permissible. Providers operating weight loss clinics can learn more about compliant compounding partnerships for their practices.
SB 1236 PBM Reform: What Texas’s Landmark Law Means for Compounding Pharmacy Access
Pharmacy benefit managers (PBMs) had been using unfair audit practices, restrictive network exclusions, and retroactive clawbacks to financially pressure independent and compounding pharmacies. These practices contributed to the closure of nearly 7% of Texas pharmacies in the year before reform.
Governor Greg Abbott signed SB 1236 in May 2025, effective September 1, 2025. The landmark law protects pharmacies from unfair audits, restrictive networks, and clawbacks. Among its key provisions, SB 1236 prohibits PBMs from denying or reducing claim payments after adjudication except in cases of fraud or clerical errors, and it establishes fair audit standards and consistent contract terms.
For patients, this legislation is designed to stabilize the market and preserve access to specialized compounding services. For providers, it means greater confidence that pharmacy partners are operating in a more financially stable environment. The National Association of Chain Drug Stores publicly applauded SB 1236 as a model for protecting pharmacy access. The lesson is consistent: choosing a financially stable, accredited compounding pharmacy protects both patients and providers from supply disruptions.
Therapeutic Areas: What Texas Compounding Pharmacies Can Customize
Compounding adds genuine clinical value when commercially available medications cannot meet a patient’s needs due to allergies, dosage requirements, discontinued formulations, or the need for alternative delivery routes.
Bio-Identical Hormone Replacement Therapy (BHRT)
BHRT is the dominant therapeutic area for compounding pharmacies by revenue. Over 1.4 million U.S. women use some form of hormone therapy, with a notable shift toward compounded BHRT. The compounding advantage is precise titration: doses can be adjusted at each refill based on lab results, something mass-manufactured products cannot offer. BHRT addresses fatigue, mood swings, weight gain, infertility, hot flashes, vaginal dryness, and sexual dysfunction. Nationwide Compounding Rx® offers BHRT in troches, transdermal creams, gels, and capsules, enabling prescribers to match the delivery route to each patient. Men’s health and testosterone replacement therapy (TRT) represent a related and growing area in Texas.
Pain Management
Topical formulations (creams, gels, and ointments) deliver active ingredients directly to the site of pain, minimizing systemic side effects such as addiction risk, dizziness, nausea, and fatigue associated with oral opioids. Compounding also allows combination formulations not commercially available. This is especially relevant for Texas pain management and sports medicine practices, and Nationwide Compounding Rx®’s sports medicine capabilities extend naturally from this work.
Dermatology
Compounded dermatology preparations address rosacea, acne, aging, scarring, stretch marks, dark spots, eczema, psoriasis, and atopic dermatitis. Formulations can be customized for individual skin types and sensitivities, including the elimination of common irritants or allergens, meeting growing demand among Texas dermatology and medical spa practices.
Pediatric Compounding
Children often cannot swallow standard pills, and commercial liquid versions may not exist or may contain allergens. Compounding addresses this with gummies, oral liquids, and suspensions in palatable flavors. Nationwide Compounding Rx® offers eight flavoring options, including banana crème, cherry, grape, raspberry, and tutti frutti, and can precisely calculate pediatric dosing not available commercially.
Specialty and Longevity Medications
The Texas market for specialty compounding, including peptides, NAD+, and longevity-focused formulations, is growing. This area requires careful attention to regulatory compliance, as not all peptides or specialty compounds are legally permissible. Veterinary compounding is also significant in Texas given the state’s large agricultural and pet-owning population.
How to Evaluate a Compounding Pharmacy in Texas: A Checklist for Patients and Providers
- PCAB Accreditation: Verify current PCAB accreditation (through ACHC), the AMA-recommended quality standard.
- USP Compliance: Confirm compliance with USP <795>, <797>, and <800> as applicable.
- TSBP Licensing and §291.133 Compliance: For sterile preparations, verify operation under the updated March 1, 2026 rules and check TSBP licensing status.
- 503A vs. 503B Classification: Match the pharmacy type to the clinical need: 503A for patient-specific prescriptions, 503B for office-use bulk orders.
- GLP-1 Compliance: Confirm that any pharmacy that previously compounded semaglutide or tirzepatide has fully wound down those operations.
- Ingredient Sourcing: Verify that active pharmaceutical ingredients (APIs) are sourced from FDA-inspected and cleared vendors.
- Turnaround and Reliability: Assess turnaround time and shipping capabilities, as supply disruptions can harm patient outcomes.
- Prescriber Collaboration: Evaluate whether the pharmacy collaborates with prescribers to optimize formulations.
Nationwide Compounding Rx® meets all of these criteria: PCAB-accredited, USP 800-compliant, 503A classified, GLP-1 compliant, FDA-inspected vendor sourcing, 1 to 2 business day turnaround, and a collaborative prescriber partnership model. Providers seeking a dedicated compounding pharmacy for medical practices can explore how Nationwide Compounding Rx® supports clinical teams.
Why Texas Patients and Providers Choose Nationwide Compounding Rx®
Nationwide Compounding Rx® is licensed and ships to Texas from its Scottsdale, Arizona facility, a common and legally sound model for compounding pharmacies serving patients across state lines.
The pharmacy has maintained PCAB accreditation since its early operations and runs a USP 800-compliant facility that eliminates cross-contamination risk. Its staff brings 40 years of combined experience across BHRT, pain management, dermatology, pediatrics, sports medicine, and weight management. A 1 to 2 business day turnaround supports patients who depend on ongoing therapy, with same-day pickup available for select medications.
All active pharmaceutical ingredients are purchased from FDA-inspected and cleared vendors. The pharmacy rejects the one-size-fits-all model, adjusting BHRT formulations at each refill based on lab results and offering allergy-friendly options that can be lactose-free, dye-free, gluten-free, and sugar-free. Available dosage forms include troches, transdermal creams, gels and ointments, capsules, gummies, oral liquids, suppositories, and lip balm. The pharmacy operates in full compliance with applicable FDA, USP, TSBP, and PCAB standards, including the GLP-1 compounding shutdown, and ships to 47 states plus Washington, D.C.
Frequently Asked Questions About Compounding Pharmacy in Texas
Is compounding legal in Texas? Yes. Compounding is legal and regulated by the TSBP under rules including §291.133 (sterile) and related non-sterile rules, with federal FDA oversight for 503B facilities.
Can patients obtain compounded semaglutide or tirzepatide from a Texas pharmacy in 2026? No. The FDA resolved both shortages (tirzepatide in December 2024, semaglutide in February 2025), and compounding “essentially a copy” of these agents is no longer legally permissible.
What is the difference between a 503A and 503B pharmacy? A 503A pharmacy compounds pursuant to a patient-specific prescription and is regulated primarily by state boards. A 503B outsourcing facility produces large batches for office use without patient-specific prescriptions and is subject to FDA CGMP oversight.
How can patients and providers identify a safe, high-quality compounding pharmacy? Look for PCAB accreditation, USP <795>/<797>/<800> compliance, TSBP licensing, and FDA-inspected ingredient sourcing. The AMA recommends partnering only with PCAB-accredited pharmacies.
Does Nationwide Compounding Rx® ship to Texas? Yes. Nationwide Compounding Rx® is licensed to ship to Texas and serves Texas patients and providers from its Scottsdale, Arizona facility.
What types of medications can be compounded for Texas patients? BHRT, pain management topicals, dermatology preparations, pediatric formulations, sports medicine compounds, and specialty medications, all pursuant to a valid patient-specific prescription.
How do the new March 1, 2026 TSBP §291.133 rules affect patients? The updated rules strengthen safety standards for sterile compounding, requiring more rigorous environmental monitoring and quality control, a clear benefit to patient safety.
Conclusion: Navigating Texas Compounding Pharmacy in 2026 with Confidence
The Texas compounding pharmacy landscape in 2026 is defined by significant regulatory change (TSBP §291.133, effective March 1, 2026), a major market disruption (the GLP-1 compounding shutdown), important patient protections (SB 1236 PBM reform), and rising quality standards (PCAB accreditation and USP <795>/<797>/<800>).
In this environment, the most important decision a Texas patient or provider can make is choosing a compounding pharmacy that is fully accredited, fully compliant, and fully committed to personalized care. The 503A versus 503B distinction, the evolving rules, and the GLP-1 enforcement actions all underscore that not all compounding pharmacies are equal, and the consequences of choosing poorly can affect patient safety and provider liability.
As a PCAB-accredited, USP 800-compliant, 503A pharmacy with 40 years of combined staff experience, a 1 to 2 business day turnaround, and a patient-by-patient approach, Nationwide Compounding Rx® is equipped to serve Texas patients and providers with the quality and compliance the 2026 environment demands. As the market grows toward a projected $10.8 to $11.5 billion by 2034, the pharmacies that earn and keep trust will be those that lead on quality, transparency, and compliance.
Partner with Nationwide Compounding Rx®: Serving Texas Patients and Providers
For providers: Texas-based healthcare providers, medical practices, and weight loss clinics seeking a PCAB-accredited, USP 800-compliant compounding pharmacy partner are encouraged to contact Nationwide Compounding Rx® to discuss patient needs.
For patients: Patients with a prescription for a compounded medication who want a trusted pharmacy that ships to Texas will find that Nationwide Compounding Rx® offers 1 to 2 business day turnaround and personalized formulations tailored to individual needs.
Contact Information:
- Toll-Free: 1-833-650-9836
- Main: 480-499-8379
- Fax: 480-699-5341
- Website: www.NationwideCompounding.com
- Hours: Monday through Friday, 7:00 a.m. to 3:30 p.m.
Nationwide Compounding Rx® collaborates directly with prescribers to optimize formulations. Providers are encouraged to call or fax prescriptions and discuss patient-specific compounding needs with the pharmacy team.
PCAB-accredited. USP 800-compliant. Patient-first. Nationwide Compounding Rx®: personalized medicine, delivered to Texas.
